BAYZF News and Press Bayer AG Registered Shares

News | Bayer AG Registered Shares (OTCMKTS:BAYZF)

BAYZF - Bayer divestiture of consumer health business would cause huge tax bill - report

2023-11-27 15:13:46 ET More on Bayer AG Breaking Up Bayer? Probably Not! Bayer Aktiengesellschaft 2023 Q3 - Results - Earnings Call Presentation Bayer Aktiengesellschaft (BAYZF) Q3 2023 Earnings Call Transcript Bayer denies knowledge of trial results before $...

BAYZF - Bayer denies knowledge of trial results before $5.75B bond sale

2023-11-24 07:28:45 ET More on Bayer, Bayer AG, etc. Breaking Up Bayer? Probably Not! Bayer Aktiengesellschaft 2023 Q3 - Results - Earnings Call Presentation Bayer Aktiengesellschaft (BAYZF) Q3 2023 Earnings Call Transcript Bayer ordered to pay $375M in Washi...

BAYZF - Bayer ordered to pay $375M in Washington over PCBs contamination

2023-11-22 07:24:12 ET More on Bayer Breaking Up Bayer? Probably Not! Bayer Aktiengesellschaft 2023 Q3 - Results - Earnings Call Presentation Bayer Aktiengesellschaft (BAYZF) Q3 2023 Earnings Call Transcript Bayer says blood thinner failed in Phase 3 trial ...

BAYZF - Bayer says blood thinner failed in Phase 3 trial

2023-11-20 08:48:57 ET More on Bayer Breaking Up Bayer? Probably Not! Bayer Aktiengesellschaft 2023 Q3 - Results - Earnings Call Presentation Bayer Aktiengesellschaft (BAYZF) Q3 2023 Earnings Call Transcript Bayer told to pay $1.56B in latest Roundup lawsuit ...

BAYZF - Bayer told to pay $1.56B in latest Roundup lawsuit

2023-11-20 07:14:14 ET More on Bayer Breaking Up Bayer? Probably Not! Bayer Aktiengesellschaft 2023 Q3 - Results - Earnings Call Presentation Bayer Aktiengesellschaft (BAYZF) Q3 2023 Earnings Call Transcript EU to extend glyphosate use for 10 more years after...

BAYZF - EU to extend glyphosate use for 10 more years after deadlock

2023-11-16 13:09:47 ET More on Bayer Breaking Up Bayer? Probably Not! Bayer Aktiengesellschaft 2023 Q3 - Results - Earnings Call Presentation Bayer Aktiengesellschaft (BAYZF) Q3 2023 Earnings Call Transcript Bayer pulling lymphoma drug from US market over fai...

BAYZF - Recursion Pharmaceuticals: Second Half 2024 Data Readouts Are Major Inflection Points

2023-11-16 12:35:07 ET Summary Recursion Pharmaceuticals, Inc. proof-of-concept data, from the phase 2 SYCAMORE study using REC-994 for the treatment of patients with Cerebral Cavernous Malformation, expected in the 2nd half of 2024. Safety and preliminary efficacy data, from the ...

BAYZF - My Dividend Stock Portfolio: New October Dividend Record - 98 Holdings With 23 Buys

2023-11-15 08:10:00 ET Summary S&P 500 and Dow Jones dropped for the third straight month in October, just before staging a remarkable reversal in November. Interest rates were kept steady again in a range of 5.25% to 5.5%, and it is uncertain if 2023 will see yet another hike...

BAYZF - Bayer pulling lymphoma drug from US market over failed study

2023-11-13 17:03:00 ET More on Bayer Breaking Up Bayer? Probably Not! Bayer Aktiengesellschaft 2023 Q3 - Results - Earnings Call Presentation Bayer Aktiengesellschaft (BAYZF) Q3 2023 Earnings Call Transcript Bayer considering breakup but not immediate three-w...

BAYZF - Breaking Up Bayer? Probably Not!

2023-11-10 10:56:34 ET Summary Bayer is reporting rather terrible third quarter results, although currency effects had a huge negative impact on the top line. Additionally, Bayer is currently discussing several options how to proceed with the business – including the possib...

Stock Information

Get BAYZF Alerts

News, Short Squeeze, Breakout and More Instantly...

Bayer AG Registered Shares Company Name:

BAYZF Stock Symbol:

OTCMKTS Market:

BAYZF - German Conglomerate Bayer Faces Investor Scrutiny Amid Unexpected Legal, Trial Setbacks | Benzinga

Bayer AG (OTC: BAYRY) (OTC: BAYZF) reportedly held an investor call to address concerns after intense scrutiny from investors following a seri...
BAYZF - Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence | Benzinga

Monday, Bayer AG (OTC: BAYRY) (OTC: BAYZF) stopped the OCEANIC-AF Phase 3 study early after asundexian showed inferiority to&nb...
BAYZF - Bayer's Blood Thinner Study Stopped Early Due To Lack Of Efficacy: Details | Benzinga

Bayer AG (OTC: BAYRY) (OTC: BAYZF) stopped the OCEANIC-AF Phase 3 study investigating asundexian compared to apixaban (a direct oral...